Comparison of adalimumab and secukinumab with respect to short-term efficacy and recurrence in moderate-tosevere psoriasis patients

Purpose: To compare the short-term efficacy and recurrence of moderate-to-severe psoriasis patients through adalimumab and secukinumab.Methods: A total of 180 patients treated in 970 Hospital of the PLA Joint Logistics Support Force from April 2019 to November 2021 were enrolled in this study. They were assigned to groups A (100 cases treated with secukinumab) and B (80 patients treated with adalimumab). Before and after treatment, the IL-23, TNF-α and 25 (OH) D levels, psoriasis area and severity index (PASI), physician global assessment (PGA), dermatology life quality index (DLQI), compliance with treatment, treatment effectiveness, incidence of adverse reactions, and short-term recurrence were assessed.Results: After treatment, the TNF-α and IL-23 levels decreased in group A, while the 25 (OH) D level increased (p < 0.05). In comparison to group B, PASI, PGA and DLQI scores in group A were lower (p < 0.05). Compliance in group A was lower (p = 0.002), while total treatment effectiveness was higher (p < 0.001). The incidence of adverse reactions (p =0.004) and frequency of short-term recurrence (p = 0.005) in group A were lower.Conclusion: The short-term efficacy of secukinumab in moderate-to-severe psoriasis patients is higherthan that of adalimumab, while recurrence is lower. Thus, secukinumab shows greater benefits than adalimumab for the treatment psoriasis